Hepatitis C virus therapeutic development: In pursuit of "perfectovir

Clinical Infectious Diseases

Volumn 60, Issue 12, 2015, Pages 1829-1836

  Dore, Gregory J ^a,b   Feld, Jordan J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Directly acting antivirals; Global access; Hepatitis c

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GLECAPREVIR; GRAZOPREVIR; GS 9857; LEDIPASVIR; MK 3682; OMBITASVIR; PARITAPREVIR PLUS RITONAVIR; PIBRENTASVIR; RIBAVIRIN; RUZASVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VELPATASVIR;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COST EFFECTIVENESS ANALYSIS; DISEASE ASSESSMENT; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LOWEST INCOME GROUP; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; HEALTH; HEPACIVIRUS; HEPATITIS C; VIROLOGY;

ANTIVIRAL AGENTS; GLOBAL HEALTH; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84941803970     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ197     Document Type: Article

References (34)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-65.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
5. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden. J Viral Hepat 2014; 21(suppl 1):1-4.
6. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. J Infect Dis 2013; 207(suppl 1):S19-S25.
7. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93:141-7.
8. Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012; 366:2436-8.
9. Cheng WS, Roberts SK, McCaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53:616-23.
10. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(suppl 1):68-77.
11. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-98.
12. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-65.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-21.
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
15. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
16. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl JMed 2014; 370:1983-92.
17. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT- 450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
18. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
19. Everson GT, Tran TT, Towner WJ, et al. Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir + GS- 5816 for 12 weeks in treatment naïve patients with genotype 1-6 HCV infection. J Hepatol 2014; 60(suppl):S46.
20. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple- drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study. Lancet 2015; 385:1107-13.
21. Thomas DL. Curing hepatitis C with pills: A step toward global control. Lancet 2010; 376:1441-2.
22. Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol 2014; 29(suppl 1): 1-9.
23. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(RR-4):1-32.
24. Shah HA, Heathcote J, Feld JJ. A Canadian screening program for hepatitis C: is now the time? CMAJ 2013; 185:1325-8.
25. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364:2199-207.
26. Baker D, Alavi M, Erratt A, et al. Delivery of treatment for hepatitis C virus infection in the primary care setting. Eur J Gastroenterol Hepatol 2014; 26:1003-9.
27. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 57(suppl 2): S62-9.
28. Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. Clin Infect Dis 2013; 57(suppl 2): S70-4.
29. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553-62.
30. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect Dis 2013; 13:288.
31. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(suppl 1):S45-s57.
32. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
33. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384:258-71.
34. Hill A, Cooke G. Medicine. Hepatitis C can be cured globally, but at what cost? Science 2014; 345:141-2.